By combining Mosaic’s proprietary phage-to-yeast display libraries with AbTherx’s Atlas Full Human Diversity (FHD) transgenic mouse platform, we capture a breadth of human-like antibody diversity, uncovering epitopes that single-platform approaches might miss.
Industry Leading Antibody Discovery & Protein Engineering
Mosaic's End-to-End Discovery Platform + AbTherx's Atlas™ Full Human Diversity Mouse
Comprehensive antibody discovery solution under a milestone- and royalty-free access model
The Mosaic Solution: Bringing all the pieces together
Working with Mosaic isn't outsourcing work- it's insourcing an expert team. Mosaic provides the entire drug discovery workflow OR just the specific services you need. Our services are designed to deliver a higher likelihood of success.
Antibody Discovery with Mosaic and AbTherx
Antibody discovery is never a one-size-fits-all approach. That's why Mosaic Biosciences has partnered with AbTherx to provide exclusive access to their revolutionary Atlas Full Human Diversity (FHD) transgenic mouse platform.
The industry-leading FHD platform in combination with Mosaic's full stack discovery workflow - including proprietary phage-to-yeast display libraries - delivers partners broader epitope coverage, greater sequence diversity, and higher-quality therapeutic candidates through comprehensive in vivo and in vitro antibody discovery and engineering services.
As the sole provider of this mouse model, Mosaic eliminates the need for partners to work with multiple service providers. We deliver a fully integrated discovery powerhouse under one roof. What's more, our milestone- and royalty-free access model provides unparalleled flexibility for teams advancing new therapeutics powered by the FHD advantage.
Our industry veteran drug hunters dive into the science with you, leveraging the Atlas platform to transform concepts into drug candidates through close collaboration and unprecedented industry experience. From ideation to IND-enabling studies and everything in between, Mosaic delivers a true partnership experience that advances your programs with exclusive access to the most sophisticated antibody discovery platforms in the industry.
Full-Stack Discovery Capabilities
Single, accountable path from design and immunization through screening, engineering, functional assays, and developability. Continuous data flow, fewer vendors, faster decisions.
Comprehensive Discovery Approaches
Combining AbTherx's advanced transgenic models and in vivo expertise with Mosaic's proprietary in vitro libraries creates complementary paths to high-quality therapeutic candidates.
Scientific Excellence & Experience
Deep expertise in transgenic model innovation and antibody discovery services, ensuring cutting-edge science, rigorous execution, and a proven track record of success.
Access Without Barriers
Milestone and royalty-free licensing model eliminates traditional restrictions, giving partners flexibility to advance programs with complete confidence and budget predictability.
Milestone & Royalty-Free Access Model
Unprecedented flexibility and budget predictability for your therapeutic programs
No hidden fees, no downstream royalties, no milestone payments. Just transparent, predictable costs that let you focus on what matters most - developing breakthrough therapies.
Your Trusted Partner
1216
(and counting) successful discovery campaigns completed
13
Marketed therapeutics discovered using technologies previously developed by AbTherx team
25+
Over 25 years of experience in protein and antibody engineering.
15k+
Customers of Elevate
Harnessing Multiple Platforms for Superior Outcomes
Leveraging multiple, complementary platforms allows us to achieve greater sequence diversity and broader epitopic coverage, improve candidate quality, and de-risk discovery programs. Ultimately, this comprehensive approach maximizes the chances of clinical success.
The superior genetic diversity across both platforms translates into a richer set of unique antibody sequences, significantly increasing the probability of identifying high-quality, therapeutically relevant candidates.
Starting with human-like antibodies from both in vivo Atlas FHD and in vitro phage-to-yeast methods, lowers developability risks and shortens timelines, driving a more efficient path toward clinical success.